Dan Bongino served his final day as deputy director of the Federal Bureau of Investigation on Saturday, returning to civilian life on Sunday after less than a year of public service.

Bongino first announced mid-December that he would be departing from the bureau in the New Year. On Saturday, Bongino made his departure official, signing off in a post on X.

‘I gave up everything for this.’

“It was a busy last day on the job,” Bongino said. “This will be my last post on this account. Tomorrow I return to civilian life.”

“It’s been an incredible year thanks to the leadership and decisiveness of President Trump,” Bongino added. “It was the honor of a lifetime to work with Director Patel, and to serve you, the American people. See you on the other side.”

RELATED: Trump suggests Dan Bongino will leave the FBI: ‘He wants to go back to his show’

Photo by Roy Rochlin/Getty Images

President Donald Trump praised Bongino, who first assumed office in March.

“Dan did a great job,” Trump said. “I think he wants to go back to his show.”

Ahead of his departure, Bongino spoke about the toll his job had taken on his personal life and his family, pointing to the demanding nature of the position.

RELATED: Bongino and Bondi clash over botched handling of Epstein files

“I gave up everything for this,” Bongino told “Fox & Friends” in a May appearance.

“I stare at these four walls all day in D.C., by myself, divorced from my wife — not divorced, but I mean separated — and it’s hard,” Bongino added. “I mean, we love each other, and it’s hard to be apart.”

Like Blaze News? Bypass the censors, sign up for our newsletters, and get stories like this direct to your inbox. Sign up here!

​Donald trump, Dan bongino, Kash patel, Fbi, Trump administration, Federal bureau of investigation, Fox & friends, Politics 

For decades, Americans heard the same justification for high drug prices. Pharmaceutical executives insisted those prices were unavoidable. Research costs required them. Innovation depended on them. The United States, as the world’s most open market, had to pay more than everyone else.

Then Eli Lilly cut the monthly price of one of its flagship weight-loss drugs, Zepbound.

If lower prices matter, then incentives matter more than bureaucracy. Competition and consumer access drive real change.

Nothing about the drug changed. No new scientific breakthrough appeared. The only thing that changed was competition. Once real pressure entered the market, Lilly found room in its pricing model that executives had long claimed did not exist.

The market responded quickly. Novo Nordisk, Lilly’s primary rival, lowered its prices soon after. This did not reflect a sudden gain in efficiency. It reflected fear of losing ground to a competitor.

That is how functioning markets work. When one major player moves, others adjust. The correction happens faster than any federal agency could hope to manage.

The irony is hard to miss. For years, the industry claimed margins were fixed and untouchable. Executives warned that any shift would damage shareholders and undermine global health. Yet the moment one company blinked, others followed. Consumers saw relief not because regulators intervened, but because competition exposed the old narrative as hollow.

Another force reinforced that shift. On Nov. 6, the White House announced a pricing agreement with major drug manufacturers scheduled to take effect in 2026. The agreement aims to narrow the gap between U.S. prices and those in other advanced economies and establishes a purchasing framework that makes reductions easier to implement.

That move marked a break from Washington’s habit of passively accepting industry talking points. The administration did not override the market. It amplified momentum competition had already created. Companies that once refused to consider cuts began to bend once the political cost of rigidity became clear. The announcement accelerated the trend, but competition started it.

A larger reality deserves attention. Major pharmaceutical companies have posted enormous profits for years. They have spent billions on stock buybacks and shareholder payouts while executive compensation soared. Market valuations across the sector reached historic highs. Lilly even became the first pharmaceutical company to surpass a trillion-dollar valuation.

Profit itself is not the problem. But competition forcing these firms to behave more like the quasi-utilities they resemble marks a welcome change from a system long treated as untouchable.

RELATED: The party that made life more expensive wants credit for noticing

byemo via iStock/Getty Images

That system rests on a global arrangement in which Americans shoulder a disproportionate share of drug development costs. Wealthy nations negotiate prices or impose caps. The United States does not. The gap between what Americans pay and what others pay funds buybacks, dividends, and executive packages. Shareholders collect the upside.

The disparity speaks for itself. Drugs that cost hundreds of dollars overseas cost thousands here. The industry defended that gap by warning that research would collapse if prices fell. The current price cuts prove otherwise. Pipelines remain intact. Investment continues. Profitability holds. The model did not break when prices moved downward. It adjusted.

These developments expose a simple truth. Prices never reflected necessity. Incentives shaped them, reinforced by limited competition and political deference. Competition cracked open an inflexible model. The White House helped widen the opening.

Policymakers should learn from that sequence. If lower prices matter, then incentives matter more than bureaucracy. Competition and consumer access drive real change. The bloated regulatory machinery Washington favors often delays it. The market moved before Congress could even respond.

For Americans struggling to afford essential medication, that lesson matters most. Competition remains the strongest and most reliable force for bringing prices down.

It worked here. It can work again — if policymakers allow markets to function and pharmaceutical companies choose access over insulation.

​Opinion & analysis, Drugs, Drug prices, Big pharma, Pharmaceutical companies, Novo nordisk, Eli lilly, Weight loss drugs, Free markets, Congress, Donald trump, Executive orders